SCHEMBL5865477

SCHEMBL5865477

c1cnc2ccc3c(c2c1)CCN3

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
KDM4E B2RXH2 5/20 0.52
CYP3A4 P08684 2/20 0.43
LMNA P02545 4/20 0.42
BLM P54132 3/20 0.42
HIF1A Q16665 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
HTT P42858 1/20 0.42
NOTUM Q6P988 1/20 0.42
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
ERN1 O75460 1/20 0.37
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
NCF1 P14598 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255938 0.90 KDM4E (0.48) MAPTKDM4ECYP3A4LMNABLM
SCHEMBL13154641 0.76 NOTUM (0.40) KDM4ECYP3A4NOTUMBCHEACHE
SCHEMBL13154665 0.75 NOTUM (0.42) NOTUMBCHEACHEPKM
SCHEMBL13154666 0.74 NOTUM (0.44) MAPTKDM4ECYP3A4LMNABLM
SCHEMBL582334 0.72 NOTUM (0.46) KDM4ELMNAHIF1AMEN1KMT2A
SCHEMBL13154679 0.71 LMNA (0.52) MAPTKDM4ECYP3A4LMNAHIF1A
SCHEMBL7375651 0.71 MAPT (0.52) MAPTKDM4ECYP3A4LMNABLM
SCHEMBL1010220 0.71 MAPT (0.43) MAPTKDM4ECYP3A4LMNABLM
SCHEMBL5773101 0.71 GSK3B (0.51) MAPTKDM4ELMNABLMHIF1A
SCHEMBL217044 0.71 MAPT (1.00) MAPTKDM4ECYP3A4LMNABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11980086-B2 Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) UDC IRELAND LIMITED (IE) 2024-05-07 US disclosed
US-20240074302-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) UDC IRELAND LTD (IE) 2024-02-29 US disclosed
WO-2022238696-A1 RADIATION-ACTIVATABLE COMPOUNDS AND USES THEREOF THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2022-11-17 WO disclosed
US-20140309428-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) BASF SE (DE) 2014-10-16 US disclosed
US-7803948-B2 Method for the isomerisation of transition metal complexes containing cyclometallated, carbene ligands BASF AKTIENGESELLSCHAFT (DE) 2010-09-28 US disclosed
US-20080200686-A1 Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands BASF AKTIENGESELLSCHAFT (DE) 2008-08-21 US disclosed
US-20080018221-A1 Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) BASF AKTIENGESELLSCHAFT (DE) 2008-01-24 US disclosed
US-7064117-B2 Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2006-06-20 US disclosed
US-20050038249-A1 Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2005-02-17 US disclosed
US-20040138195-A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2004-07-15 US disclosed
EP-1363908-A4 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM AUCKLAND UNISERVICES LTD (NZ) 2004-05-06 EP disclosed
EP-1363908-A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM Auckland Uniservices Limited (NZ) 2003-11-26 EP disclosed
WO-2002059122-A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM AUCKLAND UNISERVICES LIMITED (NZ) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138195-A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium IDH1, HIF1AN, CA2 MAPT 4825/4885KDM4E 784/4885CYP3A4 282/4885
US-20080200686-A1 Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands SCO2, CYC1, CHRM1 MAPT 4777/4885KDM4E 4387/4885CYP3A4 731/4885
US-11980086-B2 Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) OCIAD2, OCIAD1, ICOSLG MAPT 414/4885KDM4E 4325/4885CYP3A4 711/4885
US-20080018221-A1 Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) OCIAD2, OCIAD1, ICOSLG MAPT 414/4885KDM4E 4325/4885CYP3A4 711/4885
US-20240074302-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) OCIAD2, OCIAD1, ICOSLG MAPT 414/4885KDM4E 4325/4885CYP3A4 711/4885
US-20050038249-A1 Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium CA2, HIF1AN, PPOX MAPT 4817/4885KDM4E 331/4885CYP3A4 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.